Media, investors, advocacy organizations and others, please contact us here.

Publications IgAN

Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Publications IgAN

Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database

View
Publications IgAN

Sparsentan Is Superior to Losartan in the gddY Mouse Model 1 of IgA Nephropathy

View
Publications IgAN

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

View
Medical Information IgAN

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet

Posters IgAN

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy:​ Preliminary Findings From the SPARTAN Trial

Abstracts IgAN

Clinical Predictors of Major Adverse Kidney Disease Events in Patients with IgA Nephropathy

View
Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View
Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Posters IgAN

Sparsentan Reduces Proteinuria in Patients With Immunoglobulin A Nephropathy (IgAN): Interim Results of the Protect Study

Posters IgAN

Sparsentan Reduces Proteinuria in Patients With Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study

Posters IgAN

Immunoglobulin A Nephropathy (IgAN) Patient Baseline Characteristics in Asian Versus Non-Asian Regions in the Sparsentan PROTECT Study

Posters IgAN

Proteinuria and its association with disease progression in IgA nephropathy: Analysis of the UK National RaDaR IgA nephropathy cohort